• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Dupilumab for the treatment of atopic dermatitis of the elderly: a real-life 52-week experience.

作者信息

Gargiulo Luigi, Piscazzi Francesco, Ibba Luciano, Valenti Mario, Facheris Paola, Perugini Chiara, Costanzo Antonio, Narcisi Alessandra

机构信息

Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.

Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy.

出版信息

J Dermatolog Treat. 2023 Dec;34(1):2192840. doi: 10.1080/09546634.2023.2192840.

DOI:10.1080/09546634.2023.2192840
PMID:36927393
Abstract
摘要

相似文献

1
Dupilumab for the treatment of atopic dermatitis of the elderly: a real-life 52-week experience.度普利尤单抗治疗老年特应性皮炎：52周真实世界经验
J Dermatolog Treat. 2023 Dec;34(1):2192840. doi: 10.1080/09546634.2023.2192840.
2
In search of the Holy Grail in atopic dermatitis: Will dupilumab become the first disease-modifying atopic dermatitis drug?寻找特应性皮炎的圣杯：度普利尤单抗会成为首个改善病情的特应性皮炎药物吗？
J Allergy Clin Immunol. 2023 Mar;151(3):694-696. doi: 10.1016/j.jaci.2022.12.824. Epub 2023 Jan 21.
3
A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis.一项关于度普利尤单抗治疗中度至重度特应性皮炎青少年有效性和安全性的意大利多中心真实世界经验的52周更新。
J Eur Acad Dermatol Venereol. 2023 Mar;37(3):e384-e388. doi: 10.1111/jdv.18648. Epub 2022 Oct 18.
4
Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study.长期度普利尤单抗治疗老年特应性皮炎患者的疗效和安全性：一项多中心真实世界观察性研究。
Am J Clin Dermatol. 2021 Jul;22(4):581-586. doi: 10.1007/s40257-021-00597-5.
5
Real-life effectiveness and safety of dupilumab in adolescents with atopic dermatitis: a 52-week single-center retrospective study.度普利尤单抗治疗青少年特应性皮炎的真实疗效和安全性：一项为期52周的单中心回顾性研究。
J Dermatolog Treat. 2023 Apr 6;34(1):2200867. doi: 10.1080/09546634.2023.2200867.
6
Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial.度普利尤单抗治疗青少年中重度特应性皮炎的临床意义：一项随机临床试验的事后分析。
Am J Clin Dermatol. 2020 Feb;21(1):119-131. doi: 10.1007/s40257-019-00478-y.
7
A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis.度普利尤单抗治疗成人中重度特应性皮炎多中心真实世界经验的48周更新情况
J Dermatolog Treat. 2022 Mar;33(2):1146-1149. doi: 10.1080/09546634.2020.1773379. Epub 2020 Jul 3.
8
Real-life efficacy and safety of upadacitinib in adolescents with moderate-to-severe atopic dermatitis unresponsive to dupilumab: A case series.乌帕替尼治疗对度普利尤单抗无反应的中度至重度特应性皮炎青少年的真实疗效和安全性：病例系列
J Eur Acad Dermatol Venereol. 2023 Jul;37(7):e901-e903. doi: 10.1111/jdv.19011. Epub 2023 Mar 18.
9
Severe atopic dermatitis and dupilumab.重度特应性皮炎与度普利尤单抗
Rev Assoc Med Bras (1992). 2023 Feb 17;69(1):2-6. doi: 10.1590/1806-9282.023D691. eCollection 2023.
10
Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.在一项开放性研究中，度普利尤单抗为中重度特应性皮炎成人患者提供了长达 4 年的可接受安全性和持续疗效。
Am J Clin Dermatol. 2022 May;23(3):393-408. doi: 10.1007/s40257-022-00685-0. Epub 2022 May 3.

引用本文的文献

1
Phenotype-endotype relationship in elderly atopic dermatitis and effects of dupilumab therapy: prospective study.老年特应性皮炎的表型-内型关系及度普利尤单抗治疗的效果：前瞻性研究
Arch Dermatol Res. 2025 Mar 17;317(1):575. doi: 10.1007/s00403-025-04090-5.